Archana Bhaw-Luximon1, Dhanjay Jhurry2. 1. Centre for Biomedical and Biomaterials Research (CBBR), University of Mauritius, MSIRI Building, Réduit, Mauritius. 2. Centre for Biomedical and Biomaterials Research (CBBR), University of Mauritius, MSIRI Building, Réduit, Mauritius. dhanjayjhurry@gmail.com.
Abstract
PURPOSE: Three major chemotherapy strategies have emerged in the treatment of PDAC in the recent past: multiple drug combination, stroma depletion, and use of nanodrug therapy. Anti-diabetic metformin was shown to improve the outcome of a number of cancer types the first seminal report on an observational study published in 2005 and the first hospital-based case-control study on pancreatic cancer in 2009. METHODS: In this review paper, we confront the findings of a selected number of epidemiological studies and clinical trials on the use of metformin in pancreatic cancer treatment with basic knowledge and research. We particularly emphasize on the point that contradictory clinical results likely originate from heterogeneous study design due to a trial and error approach rather than an evidence-based and scientific approach. A non-rigorous selection of patients suffering from PDAC and often a poor understanding of the biological mechanism of metformin coupled with lack of scientific data has led to general statements on metformin positive or negative action, another aspect which we highlight in the review. RESULTS: We here present a few pathways which in our opinion are predominant for pancreatic cancer specifically: mitochondrial activity, AMPK activation, mTOR inhibition, and decreased IGF-1R and HIF-1α expression. CONCLUSION: We stress on the need for a better stratification of patients and a more rigorous planning of clinical trials not only focusing on classical parameters but also on potential predictive biomarkers (AMPK, mTOR, HIF-1α, IGF-1R) and metformin dosage for positive outcome.
PURPOSE: Three major chemotherapy strategies have emerged in the treatment of PDAC in the recent past: multiple drug combination, stroma depletion, and use of nanodrug therapy. Anti-diabeticmetformin was shown to improve the outcome of a number of cancer types the first seminal report on an observational study published in 2005 and the first hospital-based case-control study on pancreatic cancer in 2009. METHODS: In this review paper, we confront the findings of a selected number of epidemiological studies and clinical trials on the use of metformin in pancreatic cancer treatment with basic knowledge and research. We particularly emphasize on the point that contradictory clinical results likely originate from heterogeneous study design due to a trial and error approach rather than an evidence-based and scientific approach. A non-rigorous selection of patients suffering from PDAC and often a poor understanding of the biological mechanism of metformin coupled with lack of scientific data has led to general statements on metformin positive or negative action, another aspect which we highlight in the review. RESULTS: We here present a few pathways which in our opinion are predominant for pancreatic cancer specifically: mitochondrial activity, AMPK activation, mTOR inhibition, and decreased IGF-1R and HIF-1α expression. CONCLUSION: We stress on the need for a better stratification of patients and a more rigorous planning of clinical trials not only focusing on classical parameters but also on potential predictive biomarkers (AMPK, mTOR, HIF-1α, IGF-1R) and metformin dosage for positive outcome.
Entities:
Keywords:
Biomarkers; Cancer biology; Clinical trials; Metformin; Pancreatic cancer
Authors: Patricia Sancho; Emma Burgos-Ramos; Alejandra Tavera; Tony Bou Kheir; Petra Jagust; Matthieu Schoenhals; David Barneda; Katherine Sellers; Ramon Campos-Olivas; Osvaldo Graña; Catarina R Viera; Mariia Yuneva; Bruno Sainz; Christopher Heeschen Journal: Cell Metab Date: 2015-09-10 Impact factor: 27.287
Authors: Maria Ignez Braghiroli; Anezka C R de Celis Ferrari; Tulio Eduardo Pfiffer; Alexandra Kichfy Alex; Daniela Nebuloni; Allyne S Carneiro; Fernanda Caparelli; Luiz Senna; Juliana Lobo; Paulo Marcelo Hoff; Rachel P Riechelmann Journal: Ecancermedicalscience Date: 2015-08-11
Authors: R Alvarez; M Musteanu; E Garcia-Garcia; P P Lopez-Casas; D Megias; C Guerra; M Muñoz; Y Quijano; A Cubillo; J Rodriguez-Pascual; C Plaza; E de Vicente; S Prados; S Tabernero; M Barbacid; F Lopez-Rios; M Hidalgo Journal: Br J Cancer Date: 2013-08-01 Impact factor: 7.640
Authors: Douglas C Morran; Jianmin Wu; Nigel B Jamieson; Agata Mrowinska; Gabriela Kalna; Saadia A Karim; Amy Y M Au; Christopher J Scarlett; David K Chang; Malgorzata Z Pajak; Karin A Oien; Colin J McKay; C Ross Carter; Gerry Gillen; Sue Champion; Sally L Pimlott; Kurt I Anderson; T R Jeffry Evans; Sean M Grimmond; Andrew V Biankin; Owen J Sansom; Jennifer P Morton Journal: Gut Date: 2014-04-09 Impact factor: 23.059
Authors: Takla Griss; Emma E Vincent; Robert Egnatchik; Jocelyn Chen; Eric H Ma; Brandon Faubert; Benoit Viollet; Ralph J DeBerardinis; Russell G Jones Journal: PLoS Biol Date: 2015-12-01 Impact factor: 8.029
Authors: E Zulato; F Bergamo; A De Paoli; G Griguolo; G Esposito; G L De Salvo; C Mescoli; M Rugge; M Nardin; L Di Grazia; S Lonardi; S Indraccolo; V Zagonel Journal: Br J Cancer Date: 2014-06-03 Impact factor: 7.640
Authors: Linnéa Malgerud; Johan Lindberg; Valtteri Wirta; Maria Gustafsson-Liljefors; Masoud Karimi; Carlos Fernández Moro; Katrin Stecker; Alexander Picker; Carolin Huelsewig; Martin Stein; Regina Bohnert; Marco Del Chiaro; Stephan L Haas; Rainer L Heuchel; Johan Permert; Markus J Maeurer; Stephan Brock; Caroline S Verbeke; Lars Engstrand; David B Jackson; Henrik Grönberg; Johannes Matthias Löhr Journal: Mol Oncol Date: 2017-08-08 Impact factor: 6.603